Literature DB >> 20846100

Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.

Gemma Azaceta, Maria J Calasanz, Victoria Dourdil, Elena Bonafonte, Isabel Izquierdo, Luis Palomera.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20846100     DOI： 10.3109/10428194.2010.506567

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  3 in total

1.  Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment.

Authors:  Eleftheria Hatzimichael; Konstantinos Lagos; Amalia Vassou; Dora Gougopoulou; Alexandra Papoudou-Bai; Evangelos Briasoulis
Journal:  Mol Clin Oncol       Date:  2016-04-20

2.  Diagnosis of del(5q) MDS, 14 Years after JAK-2 Positive PV Appearance: Complete Remission of both Diseases with Lenalidomide Monotherapy.

Authors:  Antonella Vaccarino; Irene Dogliotti; Fabio Marletto; Andrea Demarchi; Mario Bazzan
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-10-20       Impact factor: 2.576

Review 3.  Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy.

Authors:  Pellegrino Musto; Vittorio Simeon; Roberto Guariglia; Gabriella Bianchino; Vitina Grieco; Filomena Nozza; Francesco La Rocca; Gioacchino Marziano; Anna Vittoria Lalinga; Emiliano Fabiani; Maria Teresa Voso; Patrizia Scaravaglio; Cristina Mecucci; Giovanni D'Arena
Journal:  Onco Targets Ther       Date:  2014-06-13       Impact factor: 4.147
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.